Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review
Open Access
- 26 September 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1254322
Abstract
Neuroblastoma is the most frequently diagnosed cancer during the first year of life. This neoplasm originates from neural crest cells derived from the sympathetic nervous system, adrenal medulla, or paraspinal ganglia. The clinical presentation can vary from an asymptomatic mass to symptoms resulting from local invasion and/or spread of distant disease spread. The natural history of neuroblastoma is highly variable, ranging from relatively indolent biological behavior to a high-risk clinical phenotype with a dismal prognosis. Age, stage, and biological features are important prognostic risk stratification and treatment assignment prognostic factors. The multimodal therapy approach includes myeloablative chemotherapy, radiotherapy, immunotherapy, and aggressive surgical resection. Hyperbaric oxygen therapy (HBOT) has been proposed as a complementary measure to overcome tumor hypoxia, which is considered one of the hallmarks of this cancer treatment resistance. This article aims to review the relevant literature on the neuroblastoma pathophysiology, clinical presentation, and different biological and genetic profiles, and to discuss its management, focusing on HBOT.Keywords
This publication has 56 references indexed in Scilit:
- The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic CancerPLOS ONE, 2013
- Hyperbaric oxygen therapy and cancer—a reviewTargeted Oncology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- High levels of HIF‐2α highlight an immature neural crest‐like neuroblastoma cell cohort located in a perivascular nicheThe Journal of Pathology, 2007
- Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotypeCancer Cell, 2006
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IVEuropean Journal of Cancer, 1995
- Tumour oxygenation under normobaric and hyperbaric conditionsBritish Journal of Radiology, 1983
- THE METABOLISM OF TUMORS IN THE BODYJournal of General Physiology, 1927